Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SUNRAY-01: LY3537982 plus pembrolizumab ± pemetrexed/platinum in first-line KRAS G12C-mutated advanced NSCLC
CTR20242544Phase 3Active
- Sponsor
- Eli Lilly and Company
- Start
- Oct 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of olomorasib in non-small cell lung cancer (NSCLC), sponsored by Eli Lilly and Company. Started Oct 2024; status: active.
02
Drugs
olomorasib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on CTR20242544.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20242544.